Alpha-1 and beta-adrenergic receptor blocking potencies of bopindolol and its two metabolites (18-502 and 20-785) as assessed by radioligand binding assay methods

Determination of bopindolol by sequential injection technique with spectrophotometric detection

In the proposed procedure, the determination of bopindolol using a sequential injection technique (SIA) with spectrophotometric detection at 560 nm is described. The new method of determination is based on the color reaction of the indole group in the molecule of bopindolol with 4-dimethylaminobenzaldehyde (Ehrlich's reagent) in acidic medium with production of a violet water-soluble complex. Due to the kinetic standpoint of reaction, the "stopped flow" technique with mixing coil between the valve and detector was tested and optimized. The proposed SIA system was used for the direct determination of bopindolol in tablets, negative effects of interfering substances (excipients of tablets) were not observed. The selectivity of the proposed method of determination was tested in the presence of seven interfering substances from the group of beta-blockers with good results. The interference effect was observed only in the presence of pindolol. The sample throughput with stopped flow technique was 40 samples per hour. Bopindolol was determined in the linear range from 1 to 10 microg ml(-1), RSD was less than 1% (n=10), with limit of detection (3sigma) 0.1 microg ml(-1) and limit of quantification 0.5 microg ml(-1). Obtained results were compared with conventional HPLC method, both analytical techniques were in good agreement.

Bopindolol: pharmacological basis and clinical implications

Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.